Moderna files for fda authorization of its updated covid-19 vaccine

Preliminary clinical data demonstrated a robust immune response by the company's xbb.1.5 monovalent vaccine against xbb descendent lineage viruses pending authorization, moderna's updated covid-19 vaccine would be available in time for fall vaccination supply readiness follows months of manufacturing to ensure timely and ample supply cambridge, ma / accesswire / june 22, 2023 / moderna, inc. (nasdaq:mrna), a biotechnology company pioneering messenger rna (mrna) therapeutics and vaccines, today announced that it has completed submission of a regulatory application to the u.s. food and drug administration for its updated covid-19 vaccine containing spike proteins for the xbb.1.5 sublineage of sars-cov-2 (mrna-1273.815). "the agility of our mrna platform has enabled us to update spikevax, moderna's covid-19 vaccine, to target xbb variants with speed and clinical rigor," said stÉphane bancel, ceo of moderna.
MRNA Ratings Summary
MRNA Quant Ranking